Madrigal Pharmaceuticals (MIL:1MDGL) Short Percentage of Float


MIL:1MDGL Madrigal Pharmaceuticals Inc MIL:1MDGL
8 GF Score
Price €416.00
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MIL:1MDGL vs BMRN, ARWR, AXSM: Short Percentage of Float Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Madrigal Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Short Percentage of Float falls into.


MIL:1MDGL
8GF Score
Madrigal Pharmaceuticals Inc MIL:1MDGL
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Madrigal Pharmaceuticals Business Description

Other Exchanges MDGL:USA0JXI:UKYDO1:Germany
Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score

Get the complete analysis for MIL:1MDGL

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€416.00
Price